Compare Tango Therapeutics Inc. (TNGX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Global X Uranium ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Global X Uranium ETF trades at $35.1 (market cap $5.50B). The key difference: Global X Uranium ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Global X Uranium ETF for 64 Days on average.
| TNGX | URA | |
|---|---|---|
Market Cap | $3.75B | $5.50B |
Volume | 9,619,106 | 3,413,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $32.90 | $61.81 |
52-Week Low | $7.50 | $35.54 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
URA (Global X Uranium ETF) trades at $37.38, down 0.9% with a bearish technical signal from moving averages. The ETF provides diversified exposure to uranium miners and nuclear energy companies amid growing global nuclear adoption. Recent news highlights nuclear energy's role in meeting AI power demand and government support for reactor development. Key holdings include Cameco (over 20%) and Sprott Physical Uranium Trust (nearly 6%).
Outlook remains mixed with strong long-term nuclear demand drivers offset by recent sector volatility. Investment opportunity lies in nuclear's capacity factor advantages and policy support, while risks include uranium price fluctuations and concentrated holdings. The ETF's 18.9% correction presents potential entry point for thematic investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
